Temsirolimus

Generic Name: Temsirolimus

Brand Names: Torisel

Drug Type: Small Molecule

Chemical Formula: C_₅₆H_₈₇NO_₁₆

CAS Number: 162635-04-3

Unique Ingredient Identifier: 624KN6GM2T

Background: Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.

Indication: For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.

Associated Conditions: Advanced Renal Cell Carcinoma

Clinical Trials

Temsirolimus in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Carcinoma
Stage IIIA Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Stage III Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Temsirolimus

First Posted Date: 2006-09-15

Last Posted Date: 2020-02-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT00376688

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma

Phase 1

Completed

Conditions: Stage IV Melanoma
Melanoma
Recurrent Melanoma
Stage III Melanoma

Interventions: Drug: sorafenib tosylate
Drug: temsirolimus

First Posted Date: 2006-07-06

Last Posted Date: 2014-04-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 69

Registration Number: NCT00349206

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase 1

Completed

Conditions: Adult Gliosarcoma
Recurrent Adult Brain Tumor
Adult Giant Cell Glioblastoma
Adult Glioblastoma

Interventions: Drug: sorafenib tosylate
Drug: erlotinib hydrochloride
Drug: temsirolimus
Drug: tipifarnib

First Posted Date: 2006-06-12

Last Posted Date: 2018-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 92

Registration Number: NCT00335764

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 4 locations

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

Phase 1

Completed

Conditions: Adult Gliosarcoma
Recurrent Adult Brain Neoplasm
Adult Glioblastoma

Interventions: Other: Laboratory Biomarker Analysis
Procedure: Conventional Surgery
Drug: Sorafenib Tosylate
Drug: Temsirolimus

First Posted Date: 2006-05-25

Last Posted Date: 2018-10-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 115

Registration Number: NCT00329719

Locations: 🇺🇸
Graham Hospital Association, Canton, Illinois, United States
🇺🇸
Illinois CancerCare-Macomb, Macomb, Illinois, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 186 locations

Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Other: pharmacological study
Procedure: adjuvant therapy
Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy
Drug: temsirolimus
Drug: temozolomide

First Posted Date: 2006-04-21

Last Posted Date: 2013-04-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 56

Registration Number: NCT00316849

Locations: 🇺🇸
Altru Cancer Center, Grand Forks, North Dakota, United States
🇺🇸
Medical Oncology and Hematology Associates, Des Moines, Iowa, United States
🇺🇸
Iowa Lutheran Hospital, Des Moines, Iowa, United States

and more 8 locations

CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: B-cell Chronic Lymphocytic Leukemia
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Marginal Zone Lymphoma
Malignant Neoplasm
Nodal Marginal Zone B-cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma

Interventions: Drug: temsirolimus

First Posted Date: 2006-02-13

Last Posted Date: 2014-05-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 89

Registration Number: NCT00290472

Locations: 🇺🇸
Decatur Memorial Hospital, Decatur, Illinois, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States

and more 10 locations

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Stage IV Melanoma
Recurrent Melanoma

Interventions: Drug: sorafenib tosylate
Drug: temsirolimus
Drug: tipifarnib

First Posted Date: 2006-01-25

Last Posted Date: 2014-05-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 109

Registration Number: NCT00281957

Locations: 🇺🇸
Contra Costa Regional Medical Center, Martinez, California, United States
🇺🇸
El Camino Hospital, Mountain View, California, United States
🇺🇸
Great Falls Clinic, Great Falls, Montana, United States

and more 170 locations

Temsirolimus in Treating Patients With Metastatic Solid Tumor or Lymphoma That Cannot Be Removed By Surgery Who Have Different Levels of Liver Function

Phase 1

Completed

Conditions: Hepatic Complications
Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: temsirolimus
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-01-11

Last Posted Date: 2013-01-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 130

Registration Number: NCT00275093

Locations: 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: sorafenib tosylate
Drug: temsirolimus
Other: laboratory biomarker analysis

First Posted Date: 2005-11-21

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00255658

Locations: 🇺🇸
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas, United States

An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients

Not Applicable

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2005-10-10

Last Posted Date: 2007-12-27

Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Target Recruit Count: 50

Registration Number: NCT00235794

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy